For the remainder of the trial, patients with or without an inherited BRCA/PALB2 mutation will be able to enroll. About General Oncology, Inc.General Oncology is a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers and other proliferative diseases. With a commitment to innovation, General Oncology is focused on advancing transformative therapies for cancer patients. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements.